<p>在最近的財報電話會議上，NeuroPace, Inc. 展示了強勁的財務表現，收入增長顯著，調整後的 EBITDA 也表現積極。儘管面臨一些挑戰，例如 DIXI 產品線的逐步結束和兒童適應症的時間延長，但整體情緒樂觀，得益於戰略進展和積極的發展。</p>
<h2>創紀錄的收入和增長</h2>
<p>NeuroPace 報告稱，2025 年第三季度的總收入創下 2740 萬美元的紀錄，同比增長 30%，而去年同期為 2110 萬美元。這一令人印象深刻的增長主要得益於 RNS 初始植入，RNS 收入達到 2260 萬美元，比去年增長 31%。</p>
<h2>積極的調整後 EBITDA</h2>
<p>NeuroPace 首次實現了正的調整後 EBITDA，突顯了公司強大的可擴展性和嚴格的費用管理。這一里程碑反映了公司在擴大市場份額的同時高效管理運營的能力。</p>
<h2>增加的收入和毛利率指引</h2>
<p>NeuroPace 將全年的收入指引上調至 9700 萬至 9800 萬美元，較之前的 9400 萬至 9800 萬美元有所提高。這一調整反映了預計 21% 至 23% 的同比增長。此外，毛利率指引也上調至 76% 至 77%，高於之前的 75% 至 76%。</p>
<h2>FDA 提交進展</h2>
<p>關於 NAUTILUS 研究和兒童適應症的進展報告，預計 NAUTILUS 的 PMA 補充申請將在年底前提交。這一進展強調了 NeuroPace 擴大產品供應和開拓新市場領域的承諾。</p>
<h2>強勁的 RNS 系統表現</h2>
<p>RNS 系統繼續表現強勁，毛利率保持在 80% 以上。這一表現得益於製造效率的提高和有利的定價，促進了公司的整體財務成功。</p>
<h2>同行認可</h2>
<p>RNS 系統因其獨特的閉環刺激能力在《臨牀神經生理學雜誌》上獲得認可，進一步鞏固了 NeuroPace 在神經刺激技術領域的領導地位。</p>
<h2>DIXI 產品線的逐步結束</h2>
<p>公司宣佈結束 DIXI 產品線，該季度銷售額約為 400 萬美元。分銷協議於 9 月 30 日正式結束，逐步結束期將持續到 2026 年第一季度末。</p>
<h2>兒童適應症的時間延長</h2>
<p>兒童適應症提交的時間表已延長至 2025 年之後，原因是需要時間來協調協議和數據集。這一延長反映了公司確保提交全面和準確的承諾。</p>
<h2>淨虧損</h2>
<p>NeuroPace 報告稱，該季度淨虧損為 350 萬美元，較去年同期的 550 萬美元淨虧損有所改善。這一淨虧損的減少表明公司在實現財務穩定方面取得了進展。</p>
<h2>前瞻性指引</h2>
<p>展望未來，NeuroPace 提供了更新的財務指引，預計季度收入創紀錄，同比增長 30%，主要得益於 RNS 初始植入。公司預計全年的收入將在 9700 萬至 9800 萬美元之間，毛利率預計將在 76% 至 77% 之間。NeuroPace 致力於維持長期增長軌跡，目標是在其核心 RNS 業務中實現至少 20% 的增長。</p>
<p>總之，NeuroPace 的財報電話會議描繪了公司財務健康和戰略方向的積極前景。憑藉創紀錄的收入增長、積極的調整後 EBITDA 和增加的指引，公司在持續成功的道路上處於良好位置。儘管面臨一些挑戰，NeuroPace 的強勁表現和前瞻性戰略為投資者和利益相關者提供了良好的前景。</p>

NPCE

<p>NeuroPace, Inc. 報告稱 2025 年第三季度創下 2740 萬美元的收入，較去年同期增長 30%，主要得益於 RNS 初始植入。該公司首次實現正向調整後息税折舊攤銷前利潤（EBITDA），反映出強勁的可擴展性。全年收入指引上調至 9700 萬至 9800 萬美元，預計毛利率為 76% 至 77%。儘管淨虧損為 350 萬美元，較去年有所改善，NeuroPace 對未來增長仍持樂觀態度，目標是在其核心 RNS 業務中實現至少 20% 的增長。該公司致力於擴展產品線並開拓新的市場領域</p>

<p>In a recent earnings call, NeuroPace, Inc. showcased a robust financial performance with strong revenue growth and positive adjusted EBITDA. Despite some challenges, such as the winding down of the DIXI product line and extended timelines for pediatric indication, the overall sentiment was optimistic, driven by strategic progress and positive developments.</p>
<div class="lb-trans"><p>在最近的財報電話會議上，NeuroPace, Inc. 展示了強勁的財務表現，收入增長顯著，調整後的 EBITDA 也表現積極。儘管面臨一些挑戰，例如 DIXI 產品線的逐步結束和兒童適應症的時間延長，但整體情緒樂觀，得益於戰略進展和積極的發展。</p>
</div><h2>Record Revenue and Growth</h2>
<div class="lb-trans"><h2>創紀錄的收入和增長</h2>
</div><p>NeuroPace reported a record total revenue of $27.4 million for Q3 2025, representing a significant 30% year-over-year growth compared to $21.1 million in the previous year. This impressive increase was primarily fueled by the RNS initial implants, with RNS revenue reaching $22.6 million, marking a 31% growth from the prior year.</p>
<div class="lb-trans"><p>NeuroPace 報告稱，2025 年第三季度的總收入創下 2740 萬美元的紀錄，同比增長 30%，而去年同期為 2110 萬美元。這一令人印象深刻的增長主要得益於 RNS 初始植入，RNS 收入達到 2260 萬美元，比去年增長 31%。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>積極的調整後 EBITDA</h2>
</div><p>For the first time in its history, NeuroPace achieved a positive adjusted EBITDA, highlighting the company’s strong scalability and disciplined expense management. This milestone reflects the company’s ability to efficiently manage its operations while expanding its market presence.</p>
<div class="lb-trans"><p>NeuroPace 首次實現了正的調整後 EBITDA，突顯了公司強大的可擴展性和嚴格的費用管理。這一里程碑反映了公司在擴大市場份額的同時高效管理運營的能力。</p>
</div><h2>Increased Revenue and Gross Margin Guidance</h2>
<div class="lb-trans"><h2>增加的收入和毛利率指引</h2>
</div><p>NeuroPace raised its full-year revenue guidance to a range of $97 million to $98 million, up from the previous guidance of $94 million to $98 million. This adjustment reflects an anticipated 21% to 23% year-over-year growth. Additionally, the gross margin guidance was increased to 76% to 77%, up from 75% to 76%.</p>
<div class="lb-trans"><p>NeuroPace 將全年的收入指引上調至 9700 萬至 9800 萬美元，較之前的 9400 萬至 9800 萬美元有所提高。這一調整反映了預計 21% 至 23% 的同比增長。此外，毛利率指引也上調至 76% 至 77%，高於之前的 75% 至 76%。</p>
</div><h2>FDA Submission Progress</h2>
<div class="lb-trans"><h2>FDA 提交進展</h2>
</div><p>Progress was reported on the NAUTILUS study and the pediatric indication, with the PMA supplement for NAUTILUS expected to be submitted by the end of the year. This advancement underscores NeuroPace’s commitment to expanding its product offerings and addressing new market segments.</p>
<div class="lb-trans"><p>關於 NAUTILUS 研究和兒童適應症的進展報告，預計 NAUTILUS 的 PMA 補充申請將在年底前提交。這一進展強調了 NeuroPace 擴大產品供應和開拓新市場領域的承諾。</p>
</div><h2>Strong RNS System Performance</h2>
<div class="lb-trans"><h2>強勁的 RNS 系統表現</h2>
</div><p>The RNS System continued to perform strongly, with a gross margin remaining above 80%. This performance was supported by improved manufacturing efficiency and favorable pricing, contributing to the company’s overall financial success.</p>
<div class="lb-trans"><p>RNS 系統繼續表現強勁，毛利率保持在 80% 以上。這一表現得益於製造效率的提高和有利的定價，促進了公司的整體財務成功。</p>
</div><h2>Peer Recognition</h2>
<div class="lb-trans"><h2>同行認可</h2>
</div><p>The RNS System received recognition in the Journal of Clinical Neurophysiology for its unique closed-loop stimulation capabilities, further establishing NeuroPace’s reputation as a leader in neurostimulation technology.</p>
<div class="lb-trans"><p>RNS 系統因其獨特的閉環刺激能力在《臨牀神經生理學雜誌》上獲得認可，進一步鞏固了 NeuroPace 在神經刺激技術領域的領導地位。</p>
</div><h2>DIXI Product Line Wind Down</h2>
<div class="lb-trans"><h2>DIXI 產品線的逐步結束</h2>
</div><p>The company announced the conclusion of its DIXI product line, with sales amounting to approximately $4 million in the quarter. The distribution agreement officially ended on September 30, and the wind-down period will continue until the end of Q1 2026.</p>
<div class="lb-trans"><p>公司宣佈結束 DIXI 產品線，該季度銷售額約為 400 萬美元。分銷協議於 9 月 30 日正式結束，逐步結束期將持續到 2026 年第一季度末。</p>
</div><h2>Extended Timeline for Pediatric Indication</h2>
<div class="lb-trans"><h2>兒童適應症的時間延長</h2>
</div><p>The timeline for the pediatric indication submission has been extended beyond 2025 due to the time required to align the protocol and data set. This extension reflects the company’s commitment to ensuring comprehensive and accurate submissions.</p>
<div class="lb-trans"><p>兒童適應症提交的時間表已延長至 2025 年之後，原因是需要時間來協調協議和數據集。這一延長反映了公司確保提交全面和準確的承諾。</p>
</div><h2>Net Loss</h2>
<div class="lb-trans"><h2>淨虧損</h2>
</div><p>NeuroPace reported a net loss of $3.5 million for the quarter, an improvement from the $5.5 million net loss in the same period last year. This reduction in net loss indicates progress towards financial stability.</p>
<div class="lb-trans"><p>NeuroPace 報告稱，該季度淨虧損為 350 萬美元，較去年同期的 550 萬美元淨虧損有所改善。這一淨虧損的減少表明公司在實現財務穩定方面取得了進展。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>Looking ahead, NeuroPace has provided updated financial guidance, projecting record quarterly revenue and a 30% year-over-year growth driven by RNS initial implants. The company expects full-year revenue to be between $97 million and $98 million, with gross margins anticipated to be between 76% and 77%. NeuroPace is committed to sustaining a long-term growth trajectory, targeting a minimum of 20% growth in its core RNS business.</p>
<div class="lb-trans"><p>展望未來，NeuroPace 提供了更新的財務指引，預計季度收入創紀錄，同比增長 30%，主要得益於 RNS 初始植入。公司預計全年的收入將在 9700 萬至 9800 萬美元之間，毛利率預計將在 76% 至 77% 之間。NeuroPace 致力於維持長期增長軌跡，目標是在其核心 RNS 業務中實現至少 20% 的增長。</p>
</div><p>In summary, NeuroPace’s earnings call painted a positive picture of the company’s financial health and strategic direction. With record revenue growth, positive adjusted EBITDA, and increased guidance, the company is well-positioned for continued success. Despite some challenges, NeuroPace’s strong performance and forward-looking strategies offer promising prospects for investors and stakeholders.</p>
<div class="lb-trans"><p>總之，NeuroPace 的財報電話會議描繪了公司財務健康和戰略方向的積極前景。憑藉創紀錄的收入增長、積極的調整後 EBITDA 和增加的指引，公司在持續成功的道路上處於良好位置。儘管面臨一些挑戰，NeuroPace 的強勁表現和前瞻性戰略為投資者和利益相關者提供了良好的前景。</p>
</div>

NeuroPace, Inc. 報告創下紀錄的收入和增長